Effect of cimetidine on gastric secretion and duodenogastric reflux

R J MELVILLE, S I SULEIMAN, P F WHITFIELD, J V PARKIN, T O NWABUNIKE, AND M HOBSLEY

From the Department of Surgical Studies, The Middlesex Hospital Medical School, London

SUMMARY In 19 subjects (four controls, one gastric ulcer and 14 duodenal ulcer) maximal gastric secretion was evoked with histamine 0.13 µmol/kg/h (0.04 mg/kg/h) for two to two and a half hours. A slow intravenous bolus dose of 200 mg cimetidine was given at the beginning of the last hour. Gastric secretion was measured before and after cimetidine administration and expressed both as mean acid output (mmol H⁺/h) and ‘pyloric loss and duodenogastric reflux corrected’ volume (Vg, ml/h). Mean reduction by acid output was 86%; mean reduction by corrected volume (Vg) was only 64%. The discrepancy, which is significant (p<0.01), is caused by a marked increase in duodenogastric reflux after cimetidine.

The H2 receptor antagonist, cimetidine, is widely used in the medical treatment of peptic ulcer disease. It is known that the primary effect of cimetidine is to competitively inhibit the stimulation, by histamine, of the parietal cells of the stomach and so reduce the amount of acid secreted.

The measurement of gastric secretion has, however, now improved so that the pyloric loss and duodenogastric reflux components of the aspirated gastric juice can be calculated separately, which allows for a more accurate determination of gastric secretion to be made. We therefore chose to re-examine the physiological effects of cimetidine on gastric secretion using this more accurate technique to improve our understanding of the function of the H2 receptor antagonists.

Method

SUBJECTS
Gastric secretion studies were carried out on 19 subjects. There were four controls (healthy volunteers) with no peptic ulcer disease, one gastric and 14 duodenal ulcer patients, with an age range of 26–67 years. No subject had taken any H2 receptor antagonist in the week before the study and no subject had been previously treated surgically.

Subjects were fasted 12 hours before the start of the study. A double lumen nasogastric tube was passed into the stomach and correctly positioned for the aspiration of gastric juice as previously described,1 with the subject in a semirecumbent position. An inert marker, PSP (phenolsulphonphthalein), was infused through the smaller lumen of the nasogastric tube at a constant rate and the gastric juice was aspirated continuously through the larger lumen of the nasogastric tube and collected as ten minute samples. A continuous intravenous infusion of histamine 0.13 µmol/kg/h (0.04 mg/kg/h) was started and maintained for two to two and a half hours. At the start of the final hour of histamine infusion a bolus dose of 200 mg cimetidine was given by slow intravenous injection. The secretion of gastric acid was expressed as a mean acid output (mmol H⁺/h) and a ‘pyloric loss and duodenogastric reflux’ corrected volume (Vg, ml/h) of the aspirated gastric juice. It should be noted that Vg is the volume of pure gastric juice secreted by the stomach – that is, the pure mixture of acid and alkaline components. Pyloric loss was calculated from the PSP concentration in the aspirated juice and duodenogastric reflux was calculated from the sodium ion concentration in the gastric aspirate as described by Whitfield and Hobsley.2 Each maximal histamine plateau was selected with the aid of a computer program based on the aspirated volumes and PSP concentration, in an effort to restrict any observer bias.2 The first sample in the cimetidine period was
Results
discarded and calculations undertaken on all subsequent samples to yield mean rates of postcimetidine secretion.

Figure 1 shows the gastric secretion for an actual subject in the study during the maximal histamine stimulation plateau and the period after cimetidine administration, measured both as acid output (mmol [H⁺]/h) and 'pyloric loss and duodenogastric reflux' corrected volume (Vg, ml/h). From acid output data, the mean reduction of acid secretion for all subjects was 86%, but from corrected volume (Vg) data the mean reduction was only 64%. The difference in the mean reduction of acid secretion by these two methods of calculation is significant (p<0.01, Wilcoxon's paired rank sum).

Figure 2 shows the percentage inhibition of acid secretion after cimetidine for each subject measured as both acid output and corrected volume (Vg). In one subject cimetidine produced no reduction in acid secretion. In two subjects there was an apparently satisfactory reduction of acid secretion by the acid output method but a less than 20% reduction by the Vg method. One subject showed no reduction by the acid output method but a greater than 50% reduction by the Vg method.

Figure 3 shows the percentage change in duodenogastric reflux after cimetidine. There is a marked increase in the volume of reflux after cimetidine (p<0.1, Wilcoxon's paired rank sum). This increase in reflux after cimetidine accounts for most of the discrepancy between acid output and Vg calculations of acid secretion.

The Table shows the mean changes, standard deviations and ranges in gastric secretion, pyloric loss, and duodenogastric reflux after cimetidine.

Pyloric loss was variable from subject to subject and showed no significant trend before or after cimetidine administration. In only one subject was it an important factor as a reduced pyloric loss after
The secretion reduced secretion.

Gastric secretion, so as Discussion for concentrations of Other composition.

bias.2 We suggested by to an of alkaline component, pylorus the reflux.
rate are calculated on the aspirate indicates a decrease.

The histamine stimulation plateau is computer generated so as to decrease the known observer bias.2 We chose to exclude the first 10 minute sample after cimetidine administration to allow time for a response to be seen in gastric secretion as suggested by studies in dogs3 and man4 which show a marked response to intravenous cimetidine from 15 to 30 minutes after administration.

The method of analysis used in this study allows a more consistent and reproducible way of assessing gastric secretion by calculating the pyloric loss and duodenogastric reflux errors of the gastric aspirate and showing the actual volume of gastric secretion during each period in the study. The formula quantifies reflux in terms of deviations from the concentrations of sodium ion expected at any given rate of secretion and the expected concentrations are calculated on the two-component hypothesis that pure gastric juice comprises a variable volume of an acid component and a fixed volume of an alkaline component, each of characteristic ionic composition. Other possible labels for reflux (bile salts, indocyanine green, bromsulphalein) have the disadvantage that they label bile rather than the whole of the duodenal contents and the information they give is about bile reflux rather than duodenogastric reflux. Mechanical markers of the duodenal contents have to be sited via a tube passing through the pylorus and clearly this factor may itself alter reflux. The sodium ion has the advantage of being an intrinsic marker uniformly distributed throughout the duodenal contents. Moreover, the sodium model is certainly accurate for maximally5 and submaximally6 stimulated secretion down to the rate of 60 ml/h and for achlorhydric patients.7 In the present study, only two subjects had a postcimetidine secretion rate of less than 60 ml/h. There are then only two subjects whose secretion rate after cimetidine fell within the narrow band of 0–60 ml/h where the secretion formula has not been validated. Even if the formula is not applicable in these two subjects their reflux was so small as to make an insignificant contribution to the reflux of the whole group. These considerations strengthen the present conclusion than duodenogastric reflux increases after cimetidine.

Gastric secretion studies, using intravenous cimetidine and calculating acid output from the aspirate directly, gave acid inhibition rates between 80% and 90%4 6 and compare closely with our result of 86%. We have shown, however, that this inhibition is not as great as it appears when the gastric aspirate is corrected for pyloric loss and duodenogastric reflux. The differences in the inhibition rates are because of the increased duodenogastric reflux component of the gastric aspirate after cimetidine which, being alkaline, neutralises some of the secreted acid in the stomach. Studies linking the healing of peptic ulcers with the reduction in acid secretion because of cimetidine must consider the duodenogastric reflux component of the aspirate if they are to be accurate and avoid the thoroughly misleading results we obtained in at least three of our subjects in this study. This is not to suggest that because cimetidine reduces true gastric secretion less than was at first supposed, it is therefore likely to be less potent in healing duodenal ulcers than we might expect. The undoubted clinical efficacy of cimetidine is presumably due to its ability to raise the pH of gastric and duodenal contents. It may not matter whether it does this completely by reducing gastric acid secretion, or partly in that way and partly by provoking retrograde movement of duodenal contents towards the pylorus.

Duodenogastric reflux occurs when there is retrograde motor activity in the duodenum with an open pylorus. There has been no study showing that cimetidine has any inhibitory action on the pylorus. Pressure studies on the lower oesophageal sphincter (LOS) by Carter et al8 using intravenous cimetidine failed to show any significant effect, although mean pressure was decreased after the cimetidine. It is possible that a higher dose (>100 mg/h) may have produced a more obvious inhibitory effect on the sphincter. Bailey et al10 suggested a bimodal effect of cimetidine on the LOS with an increase in LOS pressure at lower doses of cimetidine but a decrease in LOS pressure at higher doses after 30 minutes. Gastric emptying studies have shown no effect on

<table>
<thead>
<tr>
<th>Table Mean changes, standard deviations and ranges in gastric secretion, pyloric loss and duodenogastric reflux after cimetidine.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean</strong></td>
</tr>
<tr>
<td>Acid output mmol H+/h</td>
</tr>
<tr>
<td>Vg ml/h</td>
</tr>
<tr>
<td>Pyloric loss ml/h</td>
</tr>
<tr>
<td>Reflux ml/h</td>
</tr>
</tbody>
</table>

* Statistical significance by the Wilcoxon’s paired rank sum test. ** Negative value indicates a decrease.
the rate of gastric emptying, using single dose oral cimetidine 300 mg\textsuperscript{11} and 400 mg\textsuperscript{12} when compared with placebo. Intravenous cimetidine, given in the fasting state, has no effect on the phases of the interdigestive motor activity of the stomach or duodenum.\textsuperscript{13} There is therefore no convincing evidence to suggest a direct motor effect of cimetidine on the upper gastrointestinal tract or an indirect effect because of a decreased acid load reaching the duodenum.\textsuperscript{14} Serum gastrin concentrations after oral\textsuperscript{15} and intravenous\textsuperscript{6} cimetidine in the fasting state remain unchanged so could not indirectly account for a change in the motor activity of the stomach. The relationship between cimetidine and increased duodenogastric reflux remains to be solved by further studies.

We wish to thank Smith Kline and French for their donation of cimetidine for this study.

References

Effect of cimetidine on gastric secretion and duodenogastric reflux.

R J Melville, S I Suleiman, P F Whitfield, J V Parkin, T O Nwabunike and M Hobsley

*Gut* 1985 26: 766-769
doi: 10.1136/gut.26.8.766

Updated information and services can be found at:
http://gut.bmj.com/content/26/8/766

**Email alerting service**
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Stomach and duodenum (1689)
- Ulcer (484)
- Gastrointestinal hormones (848)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/